Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to: 1. Evaluate the safety and tolerability of KamRAB in
comparison with Human rabies immune globulin (HRIG) comparator product. 2. To assess whether
KamRAB interferes with the development of self active antibodies when given simultaneously
with active rabies vaccine, as compared to the HRIG comparator product, also given in
conjunction with the active rabies vaccine.